Clinical features of AML-MTG16 fusion gene positive acute myeloid leukemia
To investigate the clinical characteristics and possible pathogenic mechanisms of AML-MTG16 fu-sion gene-positive acute myeloid leukemia(AML)patients.The clinical data of three AML-MTG16-positive AML patients were retrospectively analyzed,and the relevant literature were reviewed to explore their clinical character-istics.This study included 3 cases of AML-MTG16 fusion gene-positive AML patients,with one male and two fe-males.The majority of patients were adults.One patient presented with an increase in eosinophil count at the ini-tial diagnosis.All 3 patients were positive for CD13,CD33,and CD34.Two cases showed co-expression of CD19,and among them,one case had weakly positive cCD79a.Additionally,one patient presented with an addi-tional abnormality of chromosome 8,two cases had GATA2 gene mutations,one patient had a KRAS gene muta-tion,and one case had concurrent mutations in BCOR gene,DNMT3A,U2AF1,and NRAS.Two cases achieved complete remission after receiving IA regimen(deoxyrubicin 12 mg/m2/d×3 d+cytarabine 100-200 mg/m2/d× 7 d)followed by transplantation,maintaining sustained complete remission.One patient achieved complete remis-sion after receiving DAC+half-ECAG(decitabine 20 mg/m2 ×3 d,aclacinomycin 20 mg,once every other day× 3 d,cytarabine 10 mg/m2,once every 12 hours×7 d,granulocyte colony-stimulating factor 300 μg,once daily× 7 d)regimen,but later relapsed and achieved CR2 after receiving HD-Arac+VP16(cytarabine 2 g/m2,once every 12 hours × 3 d,etoposide 100 mg/m2/d×6 d)regimen.AML-MTG16-positive AML is predominantly seen in a-dults,with a higher prevalence in females.Some patients may also have an increase in eosinophils,and they gen-erally have a poor prognosis.
NETL
NSTL
万方数据
